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background:  Single doses of allogeneic (donor-derived) cardiosphere-derived cells (CDCs) and mesenchymal stem cells are being 
tested clinically. Responses might be enhanced if multiple sequential doses could be safely delivered. Because allogeneic cells can 
elicit a subclinical immune reaction, repeat doses of the same cells may trigger a memory response, leading to rapid cell clearance and 
undermining efficacy. To test this possibility, we assessed cardiac function and infarct size after sequential doses of allogeneic or syngeneic 
CDCs following myocardial infarction in immunocompenent rats.
methods:  The Wistar Kyoto rat left anterior descending coronary artery was ligated and CDCs were injected intramyocardially. A second 
CDC dose was given at 3 weeks. Treatments included two doses of saline (control, n=8), human (xenogeneic, n=18), Brown Norway 
(allogeneic, n=18) or Wistar Kyoto (syngeneic, n=18) CDCs. Cardiac function was assessed by echo ejection fraction (EF), infarct size by 
Masson’s trichrome, inflammation by H&E and immune sensitization by flow cytometry for alloantibodies.
Results:  Sequential administration of allogeneic CDCs improved EF by 5.0±5.0 (first dose), 2.2±6.8 (second dose) and 7.4±7.0% 
(combined), which was equivalent to the syngeneic group (one-way ANOVA, p>.05) but significantly greater than the control and 
xenogeneic groups (p<.0001), in which EF decreased. Infarct size was equally reduced in allogeneic (11.3±2.1) and syngeneic groups 
(12.9±1.7) compared to control (19.1±1.3) and xenogeneic groups (19.7±3.0%) (one-way ANOVA, p<.0001). Linear regression confirmed 
correlation between improved EF and reduced infarct size in all groups (R2=0.6, F=52.7, p<.0001). Rejection-like mixed mononuclear cell 
infiltrates and anti-CDC IgG and IgM were present only in the xenogeneic group.
conclusion:  Two sequentially applied doses of allogeneic CDCs provide boosts in global pump function and additive scar reduction. 
Repeated doses of either syngeneic or allogeneic CDCs produce indistinguishable functional benefits. Our findings indicate that repetitive 
administration of allogeneic CDCs may be safe and effective even without immunosuppression.
